Breaking: GlaxoSmithKline PLC (LON:GSK) “Neutral” Rating Has Been Maintained at Exane BNP Paribas Today; The Target Price Provided Is GBX 1400.00


GlaxoSmithKline PLC (LON:GSK) Rating Reaffirmed

The financial firm has just set a target of GBX 1400.00 on GlaxoSmithKline PLC (LON:GSK) shares. This is 6.04% from the last stock price. In a note revealed to clients and investors on Wednesday morning, Exane BNP Paribas has reaffirmed their “Neutral” rating on shares of GSK.

From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 6 rate it a ”Buy”, 4 a “Sell”, and 20 a ”Hold”. This means that 20% of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1250. The mean of all analyst targets is GBX 1473.38 with a 11.37% above today’s (GBX 1323) stock price. GlaxoSmithKline PLC was the topic of 95 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. BNP Paribas maintained shares on December 7 with “Neutral” rating. Goldman Sachs maintained shares with “Buy” rating and GBX 1800 target share price in a report from a November 24. Liberum Capital maintained GSK stock in a recent report from December 3 with “Hold” rating. J.P. Morgan maintained the rating on November 20. J.P. Morgan has a “Neutral” rating and a GBX 1370 price target on shares. Finally, Bernstein maintained the stock with “Market Perform” rating in a report issued on a December 1.

Approximately 3.21 million shares of stock traded hands. GlaxoSmithKline plc (LON:GSK) has declined 9.10% since May 12, 2015 and is downtrending. It has underperformed by 8.30% the S&P500.

Breaking: GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 64.68 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.51 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.” Get a free copy of the Zacks research report on GlaxoSmithKline plc (GSK).